Assessing the Clinical Relevance of BRCA1 RING Domain Variants of Uncertain Significance.

Missense variants in the BRCA1 RING domain impairing BARD1 binding and homology-directed repair.

Missense variants in the BRCA1 RING domain account for a large share of the variants of uncertain significance (VUS) reported in cancer genetics, providing no information usable for clinical decision-making. The authors combined a six-feature linear support vector machine trained specifically on BRCA1 RING variants (84% accuracy in predicting in vitro binding loss) with a mammalian cell co-immunoprecipitation assay quantifying binding between variant RING constructs and endogenous BARD1. The model provided supporting classification evidence for 322 VUS, and the functional assay corroborating strong evidence for nine of them, correlating significantly with a homology-directed repair assay (p = 0.04). Taken together and interpreted under ACMG/AMP guidelines, the evidence warrants reclassification of three VUS as likely benign (N16S, A17D and E100D) and one as likely pathogenic (H41P).

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

A convincing demonstration of the value of domain-focused approaches: training the predictor and calibrating the functional assay on the RING domain alone strengthens the evidence produced, where generic predictors remain poorly discriminative. The formal yield is nonetheless modest relative to the volume screened — four reclassifications out of 322 VUS assessed — with most of the contribution remaining supporting-level evidence awaiting functional confirmation. Worth following closely for laboratories building domain-by-domain reclassification pipelines.

Analysis by Dr Thibaut Benquey